Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alkermes Plc    ALKS   IE00B56GVS15

ALKERMES PLC (ALKS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Alkermes Plc : Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc of Class Action Lawsuit and Upcoming Deadline - ALKS

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/13/2018 | 02:30pm CEST

NEW YORK, NY / ACCESSWIRE / January 13, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Alkermes plc ("Alkermes" or the "Company") (NASDAQ: ALKS) and certain of its officers. The class action, filed in United States District Court, for the Southern District of New York, and docketed under 17-cv-09178, is on behalf of a class consisting of investors who purchased or otherwise acquired Alkermes securities, seeking to recover compensable damages caused by defendants' violations of the Securities Exchange Act of 1934.

If you are a shareholder who purchased Alkermes securities between February 24, 2015, and November 3, 2017, both dates inclusive, you have until January 22, 2018, to ask the Court to appoint you as Lead Plaintiff for the class. A copy of the Complaint can be obtained at www.pomerantzlaw.com. To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and amount of shares purchased.

[Click here to join this class action]

Alkermes plc is a biopharmaceutical company focused on the development of treatments for central nervous system disorders such as addiction, schizophrenia, depression and diabetes. The Company's marketed products include Vivitrol (naltrexone for extended-release injectable suspension), a treatment for alcohol and opioid dependence.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operational and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Alkermes systemically engaged in deceptive marketing campaigns to influence policymakers to use Vivitrol in addiction treatment programs over more scientifically proven and efficacious alternatives; (ii) the foregoing conduct, when disclosed, would foreseeably subject Alkermes to heightened regulatory and legislative scrutiny; (iii) accordingly, the Company's revenues derived from Vivitrol during the Class Period were unsustainable; and (iv) as a result of the foregoing, Alkermes shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.

On June 11, 2017, The New York Times published an article entitled "Seizing On Opioid Crisis, a Drug Maker Lobbies Hard for its Product." The article described Alkermes' aggressive efforts to market Vivitrol while denigrating the efficacy of other addiction treatments.

On this news, Alkermes' share price fell $2.19, or 3.55%, to close at $59.47 on June 12, 2017

On November 6, 2017, U.S. Senator Kamala Harris announced the opening of an investigation into Alkermes' sales practices for Vivitrol. Senator Harris specifically stated that the Company "aggressively marketed" its medication, convincing judges and prison officials to use it rather than more proven addiction- treatment products, and spent hundreds of thousands of dollars lobbying policymakers. According to Harris, Alkermes promoted Vivitrol by using a "speaker's bureau composed of doctors paid to promote the drug."

On this news, Alkermes' share price fell $2.23, or 4.37%, to close at $48.76 on November 6, 2017.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP


© Accesswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ALKERMES PLC
06/08ALKERMES PLC : Wired News – Alkermes Gets License Payment from Biogen Following ..
AC
06/06ALKERMES : to Present at Goldman Sachs 39th Annual Global Healthcare Conference
PR
06/06ALKERMES : Receives $50 Million Payment From Biogen Following Review of Prelimin..
PR
05/29ALKERMES' : Corporate Presentation to be Webcast at the Jefferies 2018 Healthcar..
PR
05/23ALKERMES : to Present Data on Depression and Schizophrenia Portfolios at Upcomin..
PU
05/14ALKERMES' : Corporate Presentation to be Webcast at the UBS Global Healthcare Co..
PR
05/10ALKERMES' : Corporate Presentation to be Webcast at the Bank of America Merrill ..
PR
05/04ALKERMES : Launches Award Program To Support And Advance Central Nervous System ..
PR
05/03ALKERMES : to Host Webcast and Conference Call to Discuss ALKS 3831 Development ..
PR
05/02ALKERMES' : Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annua..
PR
More news
News from SeekingAlpha
03:28pKey events next week - healthcare 
12:05pAlkermes slumps 12% after JPM downgrade 
06/06Premarket analyst action - healthcare 
06/06Alkermes receives $50M milestone from Biogen on safety data for MS candidate .. 
05/16FDA OKs first non-opioid treatment for opioid withdrawal 
Financials ($)
Sales 2018 1 000 M
EBIT 2018 -132 M
Net income 2018 -220 M
Finance 2018 79,9 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 7,82x
EV / Sales 2019 7,04x
Capitalization 7 902 M
Chart ALKERMES PLC
Duration : Period :
Alkermes Plc Technical Analysis Chart | ALKS | IE00B56GVS15 | 4-Traders
Technical analysis trends ALKERMES PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 55,6 $
Spread / Average Target 8,2%
EPS Revisions
Managers
NameTitle
Richard F. Pops Chairman & Chief Executive Officer
James Robinson President & Chief Operating Officer
James M. Frates Chief Financial Officer & Senior Vice President
Craig C. Hopkinson Chief Medical Officer & SVP-Medicine Development
Thomas Harvey Chief Information Officer & Senior VP-IT
Sector and Competitors
1st jan.Capitalization (M$)
ALKERMES PLC-6.16%7 902
CELLTRION, INC.--.--%33 593
IQVIA HOLDINGS INC7.88%21 859
LONZA GROUP2.81%19 855
INCYTE CORPORATION-22.94%15 470
ALNYLAM PHARMACEUTICALS, INC.-17.65%10 517